Nanobiotix (NBTX) has released an update.
Nanobiotix, a late-stage clinical biotechnology company, has disclosed its updated total number of voting rights and outstanding shares as required by French law. The company, known for its innovative therapeutic approaches in oncology and other medical fields, has a strong intellectual property portfolio with over 25 patent families. Listed on both the Euronext Paris and Nasdaq, Nanobiotix maintains a commitment to expanding human life possibilities through its advanced technology platforms.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
